{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:43:30Z","timestamp":1792680210753,"version":"4.5.0"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.peptides.2025.171380","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:39:26Z","timestamp":1741696766000},"page":"171380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities"],"prefix":"10.1016","volume":"187","author":[{"given":"Clifford J.","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2025.171380_bib1","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1007\/s00125-023-05929-0","article-title":"Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy","volume":"66","author":"Tsch\u00f6p","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2025.171380_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eprac.2023.12.010","article-title":"A review of incretin therapies approved and in late-stage development for overweight and obesity management","volume":"30","author":"Chetty","year":"2024","journal-title":"Endoc. Pract."},{"key":"10.1016\/j.peptides.2025.171380_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.170939","article-title":"An update on peptide-based therapies for type 2 diabetes and obesity","volume":"161","author":"Bailey","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2025.171380_bib4","doi-asserted-by":"crossref","first-page":"71149","DOI":"10.1016\/j.peptides.2024.171149","article-title":"Recent advances in peptide-based therapies for obesity and type 2 diabetes","volume":"173","author":"Bailey","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2025.171380_bib5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s00125-023-05973-w","article-title":"Incretins and cardiovascular disease: to the heart of type 2 diabetes?","volume":"66","author":"Solini","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2025.171380_bib6","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","article-title":"Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy","volume":"66","author":"Goldney","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2025.171380_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.peptides.2025.171380_bib8","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00125-023-05956-x","article-title":"Incretin hormones and type 2 diabetes","volume":"66","author":"Nauck","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2025.171380_bib9","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.peptides.2025.171380_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.peptides.2025.171380_bib11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Brandon K, Tirzepatide versus semaglutide once weekly in patients with Type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once- weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib13","article-title":"Tirzepatide for obesity treatment and diabetes prevention","author":"Jastreboff","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment With tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.peptides.2025.171380_bib15","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"10403","key":"10.1016\/j.peptides.2025.171380_bib16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2025.171380_bib17","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/oby.24042","article-title":"Efficacy and safety of semaglutide 2.4mg by race and ethnicity: A post hoc analysis of three randomized controlled trials","volume":"32","author":"Rubino","year":"2024","journal-title":"Obes. (Silver Spring)"},{"key":"10.1016\/j.peptides.2025.171380_bib19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/dc24-0491","article-title":"Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial","volume":"47","author":"Kahn","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2025.171380_bib20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.peptides.2025.171380_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.peptides.2025.171380_bib23","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/oby.24177","article-title":"Weight maintenance on cost-effective antiobesity medications after 1\u2009year of GLP-1 receptor agonist therapy: a real-world study","volume":"32","author":"Paddu","year":"2024","journal-title":"Obesity"},{"key":"10.1016\/j.peptides.2025.171380_bib24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.peptides.2025.171380_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP)","author":"M\u00fcller","year":"2025","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"J. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib27","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/dom.15216","article-title":"The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide","volume":"25","author":"Gasbjerg","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171168","article-title":"Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes","volume":"174","author":"Bailey","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2025.171380_bib29","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0226","article-title":"The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines","volume":"261","author":"Douros","year":"2024","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.peptides.2025.171380_bib30","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s42255-024-01061-4","article-title":"Characterization of genetic variants of GIPR reveals a contribution of \u03b2-arrestin to metabolic phenotypes","volume":"6","author":"Kizilkaya","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171179","article-title":"GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells","volume":"175","author":"Shilleh","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2025.171380_bib32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cmet.2023.07.010","article-title":"GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications","volume":"35","author":"Campbell","year":"2023","journal-title":"Cell. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113326","article-title":"GLP-1 and GIP receptors signal through distinct \u03b2-arrestin 2-dependent pathways to regulate pancreatic \u03b2 cell function","volume":"42","author":"Za\u00efmia","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.peptides.2025.171380_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s42255-023-00966-w","article-title":"GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib35","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101945","article-title":"Stimulating intestinal GIP release reduces food intake and body weight in mice","volume":"84","author":"Lewis","year":"2024","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10456","key":"10.1016\/j.peptides.2025.171380_bib38","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2025.171380_bib39","unstructured":"Reuter report: Rybelsus cardiovascular outcome trial. October 2024. \u3008https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/novo-nordisks-oral-diabetes-drug-cuts-heart-related-risks-by-14-study-2024-10-21\/easd\/ada\u3009 guideline."},{"key":"10.1016\/j.peptides.2025.171380_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: Comprehensive Type 2 diabetes management algorithm - 2023 Update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr., Pract."},{"key":"10.1016\/j.peptides.2025.171380_bib41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-024-02180-8","article-title":"VOT summit report 2023: new cardiovascular, kidney, and metabolic outcomes","volume":"23","author":"Schnell","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.peptides.2025.171380_bib42","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib43","article-title":"Tirzepatide for heart Failure with preserved ejection fraction and obesity","author":"Packer","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib44","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.peptides.2025.171380_bib46","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3390\/ph16060836","article-title":"Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective","volume":"16","author":"Pandey","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.peptides.2025.171380_bib47","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.peptides.2025.171380_bib48","doi-asserted-by":"crossref","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.peptides.2025.171380_bib49","article-title":"Anti-atherosclerotic effect of incretin receptor agonists","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.peptides.2025.171380_bib50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1126\/science.adn4128","article-title":"The benefits of GLP-1 drugs beyond obesity","volume":"385","author":"Drucker","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.peptides.2025.171380_bib51","unstructured":"Medicines and Healthcare Products Regulatory Agency. Press release. MHRA approves GLP \u20131 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults, 23 July 2024. \u3008https:\/\/www.gov.uk\/government\/news\/mhra-approves-glp-1-receptor-agonist-semaglutide-to-reduce-risk-of-serious-heart-problems-in-obese-or-overweight-adults\u3009."},{"key":"10.1016\/j.peptides.2025.171380_bib52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-024-02319-7","article-title":"Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.peptides.2025.171380_bib53","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/23969873241234238","article-title":"Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP\/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis","volume":"9","author":"Stefanou","year":"2024","journal-title":"Eur. Stroke J."},{"key":"10.1016\/j.peptides.2025.171380_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.peptides.2025.171380_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12933-023-01940-2","article-title":"GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease","volume":"22","author":"Sachs","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.peptides.2025.171380_bib56","doi-asserted-by":"crossref","first-page":"9724","DOI":"10.3390\/ijms25179724","article-title":"Glucose-dependent insulinotropic polypeptide inhibits AGE-induced NADPH oxidase-derived oxidative stress generation and foam cell formation in macrophages partly via AMPK activation","volume":"25","author":"Terasaki","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.peptides.2025.171380_bib57","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.peptides.2025.171380_bib58","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/dom.14776","article-title":"Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"24","author":"Yuan","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib59","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/dc22-1889","article-title":"Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without Type 2 diabetes: Exploratory analysis from the STEP 1, 2, and 3 trials","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2025.171380_bib60","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with Type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib62","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","author":"Apperloo","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib63","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/dom.15410","article-title":"Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib64","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1111\/dom.15967","article-title":"Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study","volume":"26","author":"Vanek","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib65","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eprac.2024.07.008","article-title":"The Use of semaglutide in patients with renal failure - a retrospective cohort study","volume":"30","author":"Long","year":"2024","journal-title":"Endoc. Pract."},{"key":"10.1016\/j.peptides.2025.171380_bib66","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products\u2013induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.peptides.2025.171380_bib67","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41581-024-00876-4","article-title":"The GLP-1 receptor agonist revolution comes to nephrology","volume":"20","author":"Thomas","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.peptides.2025.171380_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1379189","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","volume":"11","author":"Masson","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib69","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13098-023-01118-6","article-title":"The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials","volume":"15","author":"Yu","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.peptides.2025.171380_bib72","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s10787-023-01239-4","article-title":"Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach","volume":"31","author":"Batiha","year":"2023","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.peptides.2025.171380_bib73","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2024.08.007","article-title":"The Effect of semaglutide on mortality and COVID-19\u2013related deaths: an analysis from the SELECT trial","volume":"84","author":"Scirica","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.peptides.2025.171380_bib74","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2025.171380_bib75","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.peptides.2025.171380_bib76","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","article-title":"The emerging role of glucagon- like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"22","author":"Abushamat","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2025.171380_bib77","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.peptides.2025.171380_bib78","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1007\/s00125-023-05966-9","article-title":"The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease","volume":"66","author":"Andreasen","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2025.171380_bib79","article-title":"Semaglutide improves metabolic dysfunction-associated steatohepatitis: A 10-year retrospective study","volume":"8","author":"Shah","year":"2024","journal-title":"J. Gastroenterol. Hepatol. Open"},{"key":"10.1016\/j.peptides.2025.171380_bib80","first-page":"218","article-title":"GLP1 agonists and risk of major adverse liver outcomes","volume":"21","author":"Ray","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2025.171380_bib81","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib82","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.16755","article-title":"Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight\/obesity in elderly population: a nationwide cohort study","author":"Kim","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2025.171380_bib83","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib84","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pcd.2024.03.005","article-title":"Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis","volume":"18","author":"Fang","year":"2024","journal-title":"Prim. Care Diabetes"},{"key":"10.1016\/j.peptides.2025.171380_bib85","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"al., Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.peptides.2025.171380_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1205207","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: A systematic review and meta-analysis of preclinical studies","volume":"14","author":"Kong","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.peptides.2025.171380_bib88","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","article-title":"Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"31","author":"Hong","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.peptides.2025.171380_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101470","article-title":"GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes","volume":"49","author":"Monney","year":"2023","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib90","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.peptides.2025.171380_bib91","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1134\/S1819712423020204","article-title":"Glucagon-like peptide 1 receptor agonists in Alzheimer\u2019s disease","volume":"17","author":"Wang","year":"2023","journal-title":"Neurochem. J."},{"key":"10.1016\/j.peptides.2025.171380_bib92","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in Parkinson\u2019s disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.peptides.2025.171380_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dia.2024.0328","article-title":"Effectiveness of semaglutide and tirzepatide in overweight and obese adults with Type 1 diabetes","volume":"27","author":"Snell-Bergeon","year":"2025","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.peptides.2025.171380_bib94","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.peptides.2025.171380_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.975880","article-title":"Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus","volume":"14","author":"Tan","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.peptides.2025.171380_bib96","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1111\/dom.15979","article-title":"Effects of glucagon-like peptide-1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib97","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40261-024-01405-8","article-title":"Pharmacokinetic properties of a once-weekly fixed-ratio combination of insulin icodec and semaglutide compared with separate administration of each component in individuals with Type 2 diabetes mellitus","volume":"44","author":"Westergaard","year":"2024","journal-title":"Clin. Drug. Investig."},{"key":"10.1016\/j.peptides.2025.171380_bib98","doi-asserted-by":"crossref","DOI":"10.1177\/11795514241238059","article-title":"Gut-derived peptide hormone analogues and potential treatment of bone disorders in obesity and diabetes mellitus","volume":"17","author":"Ali","year":"2024","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"10.1016\/j.peptides.2025.171380_bib99","article-title":"Effects of incretin therapy on skeletal health in Type 2 diabetes - A systematic review","volume":"7","author":"Viggers","year":"2023","journal-title":"JBMR"},{"key":"10.1016\/j.peptides.2025.171380_bib100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00223-024-01240-1","article-title":"Glucagon-like peptide-1 receptor agonists and diabetic osteopathy: Another positive effect of incretines? A 12 Months longitudinal study","volume":"115","author":"Al Refaie","year":"2024","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.peptides.2025.171380_bib101","doi-asserted-by":"crossref","DOI":"10.1002\/phar.70005","article-title":"The potential role of GLP-1 receptor agonists in osteoarthritis","author":"Ryan","year":"2025","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.peptides.2025.171380_bib102","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib103","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/diseases12090224","article-title":"Therapeutic potential of glucagon-like peptide-1 receptor agonists in obstructive sleep apnea syndrome management: A narrative review","volume":"12","author":"Dragonieri","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.peptides.2025.171380_bib104","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13098-023-01118-6","article-title":"The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials","volume":"15","author":"Yu","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.peptides.2025.171380_bib106","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2025.171380_bib107","article-title":"Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities","author":"Bettadapura","year":"2024","journal-title":"Int. J. Obes. (Lond. )"},{"key":"10.1016\/j.peptides.2025.171380_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.peptides.2025.171380_bib109","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euroneuro.2024.07.001","article-title":"GLP-1 agonists and risk of suicidal thoughts and behaviours: Confound by indication once again? A narrative review","volume":"87","author":"Strumila","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.peptides.2025.171380_bib110","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib111","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s40501-024-00331-y","article-title":"The impact of GLP-1 receptor agonists (GLP-1 RAs) on mental health: A systematic review","volume":"11","author":"Tempia Valenta","year":"2024","journal-title":"Curr. Treat. Options Psych."},{"key":"10.1016\/j.peptides.2025.171380_bib112","unstructured":"R.L. Dubin, S.B. Heymsfield, E. Ravussin, F.L. Greenway, Glucagon-like peptide-1 receptor."},{"key":"10.1016\/j.peptides.2025.171380_bib113","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanhl.2024.07.004","article-title":"Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study","volume":"5","author":"Hsiao","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.peptides.2025.171380_bib115","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2025.171380_bib116","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/oby.24222","article-title":"Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial","author":"Kushner","year":"2025","journal-title":"Obes. (Silver Spring)"},{"key":"10.1016\/j.peptides.2025.171380_bib118","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4239\/wjd.v14.i4.424","article-title":"Semaglutide-eye-catching results","volume":"14","author":"Cigrovski Berkovic","year":"2023","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.peptides.2025.171380_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.endmts.2024.100168","article-title":"Long-term use of semaglutide and risk of diabetic retinopathy progression","volume":"15","author":"Stevens","year":"2024","journal-title":"Endocr. Metab. Sci."},{"key":"10.1016\/j.peptides.2025.171380_bib120","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.peptides.2025.171380_bib121","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int. J. Retin. Vitr."},{"key":"10.1016\/j.peptides.2025.171380_bib122","first-page":"S0161","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: A multinational population-based study","author":"Chou","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.peptides.2025.171380_bib123","unstructured":"FDA warns consumers. U.S. Food & Drug Administration, 21 December 2023. \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain\u3009."},{"key":"10.1016\/j.peptides.2025.171380_bib124","unstructured":"WHO issues warning. World Health Organization, 24 June 2024. \u3008https:\/\/www.who.int\/news\/item\/20-06-2024-who-issues-warning-on-falsified-medicines-used-for-diabetes-treatment-and-weight-loss\u3009."},{"key":"10.1016\/j.peptides.2025.171380_bib125","article-title":"Compounded GLP 1 and dual GIP\/GLP 1 receptor agonists: A statement from the American Diabetes Association","author":"Neumiller","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2025.171380_bib126","doi-asserted-by":"crossref","first-page":"8168","DOI":"10.1038\/s41467-023-44074-5","article-title":"Total wash elimination for solid phase peptide synthesis","volume":"14","author":"Collins","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2025.171380_bib127","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"eClinical Med"},{"key":"10.1016\/j.peptides.2025.171380_bib128","article-title":"What is the pipeline for future medications for obesity?","author":"Melson","year":"2024","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2025.171380_bib129","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"389","author":"Wharton","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"10400","key":"10.1016\/j.peptides.2025.171380_bib130","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2025.171380_bib131","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.1038\/s41467-024-52353-y","article-title":"Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2025.171380_bib132","unstructured":"H. Zhou, L. Ji, X. Song, Y. Zhang, X., Xu X. Li et al., ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1c study, Diabetologia 67, suppl.1 (20240 abstract 147."},{"key":"10.1016\/j.peptides.2025.171380_bib133","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.peptides.2025.171380_bib134","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.peptides.2025.171380_bib135","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Efficacy and safety of mazdutide in Chinese patients with Type 2 diabetes: A randomized, double-blind, placebo-controlled Phase 2 trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2025.171380_bib136","article-title":"Characterization of LY3324954 a long-acting glucagon-receptor agonist","volume":"91","author":"Coskun","year":"2025","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2025.171380_bib137","first-page":"435","article-title":"Targeting energy expenditure-drugs for obesity treatment","volume":"14","author":"Jimenez-Munoz","year":"2021","journal-title":"Pharm. (Basel)"},{"issue":"10401","key":"10.1016\/j.peptides.2025.171380_bib138","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2025.171380_bib139","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - A phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2025.171380_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107176","article-title":"A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study","volume":"130","author":"Abdelmalek","year":"2023","journal-title":"Contemp. Clin. Trials"},{"issue":"l1","key":"10.1016\/j.peptides.2025.171380_bib141","article-title":"Safety, pharmacokinetics, and pharmacodynamics of CT-388, a signal-biased dual GLP-1\/GIP receptor agonist, over 24 weeks in adults with obesity","volume":"67","author":"Chakravarthy","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2025.171380_bib142","unstructured":"Viking Therapeutics Press Release, 4 Nov 2024. \u3008https:\/\/ir.vikingtherapeutics.com\/2024-11-04\u3009."},{"key":"10.1016\/j.peptides.2025.171380_bib143","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.1038\/s41467-024-54080-w","article-title":"The dual GLP-1\/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk","volume":"15","author":"Valdecantos","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2025.171380_bib144","unstructured":"Amgen. MarTide update, 26 November 2034, \u3008https:\/\/investors.amgen.com\/static-files\/0176d78e-920b-45b3-b9cc-a727e58e80da\u3009."},{"key":"10.1016\/j.peptides.2025.171380_bib145","first-page":"1","article-title":"Amylin analogs for the treatment of obesity without diabetes: present and future","author":"Panou","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"10403","key":"10.1016\/j.peptides.2025.171380_bib146","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"S, et al., Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74mg with once-weekly semaglutide 2.4mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2025.171380_bib147","unstructured":"Novo Nordisk A\/S Company Announcement: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial. \u3008https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=\u2009915082\u3009."},{"issue":".","key":"10.1016\/j.peptides.2025.171380_bib148","first-page":"1","article-title":"Safety, tolerability and weight reduction findings of oral: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study","volume":"67","author":"Gasiorek","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2025.171380_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114969","article-title":"Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss","volume":"164","author":"Larsen","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.peptides.2025.171380_bib150","doi-asserted-by":"crossref","first-page":"E145","DOI":"10.1152\/ajpendo.00092.2024","article-title":"The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes","volume":"327","author":"Larsen","year":"2024","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":".1","key":"10.1016\/j.peptides.2025.171380_bib151","article-title":"Novel unimolecular tetra-agonist peptides targeting GLP-1, GIP, amylin, and calcitonin receptors with enhanced metabolic benefits in animal models of obesity","volume":"67","author":"Rondinone","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2025.171380_bib152","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.3390\/biom14121520","article-title":"Comparative effects of GLP-1 and GLP-2 on beta-cell function, glucose homeostasis and appetite regulation","volume":"14","author":"Ali","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.peptides.2025.171380_bib153","doi-asserted-by":"crossref","first-page":"179 171256","DOI":"10.1016\/j.peptides.2024.171256","article-title":"NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?","volume":"179","author":"Lafferty","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2025.171380_bib154","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41586-024-08207-0","article-title":"NK2R control of energy expenditure and feeding to treat metabolic diseases","volume":"635","author":"Sass","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.peptides.2025.171380_bib155","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.7150\/thno.61747","article-title":"Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.peptides.2025.171380_bib156","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.41380","article-title":"Metabolic bariatric surgery in the era of GLP-1 receptor agonists for obesity management","volume":"7","author":"Lin","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.peptides.2025.171380_bib157","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0196-9781(81)90008-5","article-title":"Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities","volume":"2","author":"Bataille","year":"1981","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2025.171380_bib158","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.molmet.2013.12.001","article-title":"Action and therapeutic potential of oxyntomodulin","volume":"3","author":"Pocai","year":"2013","journal-title":"Mol. Metab."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978125000415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978125000415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T16:38:24Z","timestamp":1744130304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978125000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":158,"alternative-id":["S0196978125000415"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2025.171380","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2025.171380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"171380"}}